Obesity and prostate cancer detection

Insights from three national surveys

Niyati Parekh, Yong Lin, Robert S. Dipaola, Stephen Marcella, Grace Lu-Yao

Research output: Contribution to journalArticle

Abstract

Background: Previous studies suggest that obesity is associated with higher prostate cancer progression and mortality despite an association with lower prostate cancer incidence. This study aims to better understand these apparently inconsistent relationships among obese men by combining evidence from 3 nationally representative cross-sectional surveys. Methods: We evaluated relationships between obesity and 1) testosterone concentrations in the Third National Health and Nutrition Examination Survey (NHANES III; n = 845); 2) prostate-specific antigen (PSA) in NHANES 2001-2004 (n = 2458); and 3) prostate biopsy rates in the National Health Interview Survey (NHIS 2000; n = 4789) population. Mean testosterone, PSA concentrations, and biopsy rates were computed for Body Mass Index (BMI) categories. Results: Testosterone concentrations were inversely associated with obesity (P-trend <.0001) in NHANES III. In NHANES 2001-2004, obese (BMI >35) versus lean (BMI <25) men were less likely to have PSA concentrations that reached the biopsy threshold of >4 ng/mL (3% vs 8%; P <.0001). Among NHIS participants, all BMI groups had similar rates of PSA testing (P = .24). However, among men who had PSA tests, 11% of men with BMI >30 versus 16% with BMI <25, achieved a PSA threshold of 4 ng/mL; P = .01. Furthermore, biopsy rates were lower among men with BMI >30 versus BMI <25 in NHIS participants (4.6% vs 5.8%; P = .05). Conclusions: Obesity was associated with lower PSA-driven biopsy rates. These data support further studies to test the hypothesis that obesity affects prostate cancer detection independent of prostate cancer risk by decreasing the PSA-driven biopsy rates.

Original languageEnglish (US)
Pages (from-to)829-835
Number of pages7
JournalAmerican Journal of Medicine
Volume123
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Obesity
Nutrition Surveys
Body Mass Index
Biopsy
Testosterone
Health Surveys
Prostate
Cross-Sectional Studies
Surveys and Questionnaires
Interviews
Mortality
Incidence
Population

Keywords

  • Biopsy
  • Detection
  • Obesity
  • Prostate cancer
  • Prostate-specific antigen
  • PSA

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Obesity and prostate cancer detection : Insights from three national surveys. / Parekh, Niyati; Lin, Yong; Dipaola, Robert S.; Marcella, Stephen; Lu-Yao, Grace.

In: American Journal of Medicine, Vol. 123, No. 9, 09.2010, p. 829-835.

Research output: Contribution to journalArticle

Parekh, Niyati ; Lin, Yong ; Dipaola, Robert S. ; Marcella, Stephen ; Lu-Yao, Grace. / Obesity and prostate cancer detection : Insights from three national surveys. In: American Journal of Medicine. 2010 ; Vol. 123, No. 9. pp. 829-835.
@article{7b73db5859b3458c9a91c3e528f46e0e,
title = "Obesity and prostate cancer detection: Insights from three national surveys",
abstract = "Background: Previous studies suggest that obesity is associated with higher prostate cancer progression and mortality despite an association with lower prostate cancer incidence. This study aims to better understand these apparently inconsistent relationships among obese men by combining evidence from 3 nationally representative cross-sectional surveys. Methods: We evaluated relationships between obesity and 1) testosterone concentrations in the Third National Health and Nutrition Examination Survey (NHANES III; n = 845); 2) prostate-specific antigen (PSA) in NHANES 2001-2004 (n = 2458); and 3) prostate biopsy rates in the National Health Interview Survey (NHIS 2000; n = 4789) population. Mean testosterone, PSA concentrations, and biopsy rates were computed for Body Mass Index (BMI) categories. Results: Testosterone concentrations were inversely associated with obesity (P-trend <.0001) in NHANES III. In NHANES 2001-2004, obese (BMI >35) versus lean (BMI <25) men were less likely to have PSA concentrations that reached the biopsy threshold of >4 ng/mL (3{\%} vs 8{\%}; P <.0001). Among NHIS participants, all BMI groups had similar rates of PSA testing (P = .24). However, among men who had PSA tests, 11{\%} of men with BMI >30 versus 16{\%} with BMI <25, achieved a PSA threshold of 4 ng/mL; P = .01. Furthermore, biopsy rates were lower among men with BMI >30 versus BMI <25 in NHIS participants (4.6{\%} vs 5.8{\%}; P = .05). Conclusions: Obesity was associated with lower PSA-driven biopsy rates. These data support further studies to test the hypothesis that obesity affects prostate cancer detection independent of prostate cancer risk by decreasing the PSA-driven biopsy rates.",
keywords = "Biopsy, Detection, Obesity, Prostate cancer, Prostate-specific antigen, PSA",
author = "Niyati Parekh and Yong Lin and Dipaola, {Robert S.} and Stephen Marcella and Grace Lu-Yao",
year = "2010",
month = "9",
doi = "10.1016/j.amjmed.2010.05.011",
language = "English (US)",
volume = "123",
pages = "829--835",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Obesity and prostate cancer detection

T2 - Insights from three national surveys

AU - Parekh, Niyati

AU - Lin, Yong

AU - Dipaola, Robert S.

AU - Marcella, Stephen

AU - Lu-Yao, Grace

PY - 2010/9

Y1 - 2010/9

N2 - Background: Previous studies suggest that obesity is associated with higher prostate cancer progression and mortality despite an association with lower prostate cancer incidence. This study aims to better understand these apparently inconsistent relationships among obese men by combining evidence from 3 nationally representative cross-sectional surveys. Methods: We evaluated relationships between obesity and 1) testosterone concentrations in the Third National Health and Nutrition Examination Survey (NHANES III; n = 845); 2) prostate-specific antigen (PSA) in NHANES 2001-2004 (n = 2458); and 3) prostate biopsy rates in the National Health Interview Survey (NHIS 2000; n = 4789) population. Mean testosterone, PSA concentrations, and biopsy rates were computed for Body Mass Index (BMI) categories. Results: Testosterone concentrations were inversely associated with obesity (P-trend <.0001) in NHANES III. In NHANES 2001-2004, obese (BMI >35) versus lean (BMI <25) men were less likely to have PSA concentrations that reached the biopsy threshold of >4 ng/mL (3% vs 8%; P <.0001). Among NHIS participants, all BMI groups had similar rates of PSA testing (P = .24). However, among men who had PSA tests, 11% of men with BMI >30 versus 16% with BMI <25, achieved a PSA threshold of 4 ng/mL; P = .01. Furthermore, biopsy rates were lower among men with BMI >30 versus BMI <25 in NHIS participants (4.6% vs 5.8%; P = .05). Conclusions: Obesity was associated with lower PSA-driven biopsy rates. These data support further studies to test the hypothesis that obesity affects prostate cancer detection independent of prostate cancer risk by decreasing the PSA-driven biopsy rates.

AB - Background: Previous studies suggest that obesity is associated with higher prostate cancer progression and mortality despite an association with lower prostate cancer incidence. This study aims to better understand these apparently inconsistent relationships among obese men by combining evidence from 3 nationally representative cross-sectional surveys. Methods: We evaluated relationships between obesity and 1) testosterone concentrations in the Third National Health and Nutrition Examination Survey (NHANES III; n = 845); 2) prostate-specific antigen (PSA) in NHANES 2001-2004 (n = 2458); and 3) prostate biopsy rates in the National Health Interview Survey (NHIS 2000; n = 4789) population. Mean testosterone, PSA concentrations, and biopsy rates were computed for Body Mass Index (BMI) categories. Results: Testosterone concentrations were inversely associated with obesity (P-trend <.0001) in NHANES III. In NHANES 2001-2004, obese (BMI >35) versus lean (BMI <25) men were less likely to have PSA concentrations that reached the biopsy threshold of >4 ng/mL (3% vs 8%; P <.0001). Among NHIS participants, all BMI groups had similar rates of PSA testing (P = .24). However, among men who had PSA tests, 11% of men with BMI >30 versus 16% with BMI <25, achieved a PSA threshold of 4 ng/mL; P = .01. Furthermore, biopsy rates were lower among men with BMI >30 versus BMI <25 in NHIS participants (4.6% vs 5.8%; P = .05). Conclusions: Obesity was associated with lower PSA-driven biopsy rates. These data support further studies to test the hypothesis that obesity affects prostate cancer detection independent of prostate cancer risk by decreasing the PSA-driven biopsy rates.

KW - Biopsy

KW - Detection

KW - Obesity

KW - Prostate cancer

KW - Prostate-specific antigen

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=77956200385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956200385&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2010.05.011

DO - 10.1016/j.amjmed.2010.05.011

M3 - Article

VL - 123

SP - 829

EP - 835

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 9

ER -